NCT00763763View on ClinicalTrials.gov

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

January 31, 2010

Conditions

Leukemia, Lymphocytic, AcutePhiladelphia ChromosomeBlast CrisisLeukemia, Myeloid, Chronic

Interventions

DRUG

Imatinib mesylate

imatinib 600 mg/day for 2 years

DRUG

Interferon

45 micrograms per week during 2 years

DRUG

Vincristine

2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation

DRUG

Dexamethasone

40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation

Trial Locations (1)

75010

Service Clinique des Maladies du Sang, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00763763 - Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive | Biotech Hunter | Biotech Hunter